TCG Crossover Management, LLC
TCG Crossover Management, LLC reported 54 holdings worth US$4.16B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
TCG Crossover Management, LLC reported 54 holdings worth US$4.16B as of Jun 30, 2026. Largest: Abivax Sa, Tango Therapeutics, Inc. and Cg Oncology, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 54
- Value as reported
- US$4.16B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Abivax Sa | 6.01M | US$801M | 19.2% |
| Tango Therapeutics, Inc. | 9.08M | US$284M | 6.8% |
| Cg Oncology, Inc. | 3.67M | US$261M | 6.3% |
| Cogent Biosciences, Inc. | 4.85M | US$188M | 4.5% |
| Immunovant, Inc. | 4.46M | US$172M | 4.1% |
| Spyre Therapeutics, Inc. | 1.9M | US$169M | 4.1% |
| Dianthus Therapeutics, Inc. | 1.68M | US$163M | 3.9% |
| Mirum Pharmaceuticals, Inc. | 1.06M | US$124M | 3.0% |
| Zai Lab Ltd. | 6.14M | US$117M | 2.8% |
| Amylyx Pharmaceuticals, Inc. | 6.24M | US$112M | 2.7% |
| Monte Rosa Therapeutics, Inc. | 4.62M | US$112M | 2.7% |
| Biocryst Pharmaceuticals, Inc. | 11M | US$110M | 2.6% |
| Vor Biopharma Inc. | 5.67M | US$104M | 2.5% |
| Tyra Biosciences, Inc. | 3.25M | US$104M | 2.5% |
| Dyne Therapeutics, Inc. | 4.62M | US$103M | 2.5% |
| Disc Medicine, Inc. | 1.34M | US$98.1M | 2.4% |
| Relay Therapeutics, Inc. | 4.27M | US$80M | 1.9% |
| Savara, Inc. | 12.4M | US$76.2M | 1.8% |
| Aura Biosciences, Inc. | 9.53M | US$67.7M | 1.6% |
| Revolution Medicines, Inc. | 341K | US$63.8M | 1.5% |
| First Tracks Biotherapeutics, Inc. | 2.9M | US$58.3M | 1.4% |
| Kodiak Sciences Inc | 1.45M | US$56.3M | 1.4% |
| Avalo Therapeutics, Inc. | 3.02M | US$55.8M | 1.3% |
| Lb Pharmaceuticals Inc | 1.45M | US$47M | 1.1% |
| Century Therapeutics, Inc. | 17.8M | US$43.4M | 1.0% |
| Tectonic Therapeutic, Inc. | 1.2M | US$41.4M | 1.00% |
| Xencor, Inc. | 2.45M | US$39.5M | 0.95% |
| Surrozen, Inc. | 1.47M | US$38.2M | 0.92% |
| Editas Medicine, Inc. | 11.1M | US$36M | 0.87% |
| Mbx Biosciences, Inc. | 650K | US$35.9M | 0.86% |
| Altimmune, Inc. | 10M | US$30.4M | 0.73% |
| Janux Therapeutics, Inc. | 1.79M | US$27.5M | 0.66% |
| Perspective Therapeutics, Inc. | 7.92M | US$27M | 0.65% |
| Biohaven Ltd. | 1.78M | US$26.5M | 0.64% |
| Aktis Oncology, Inc. | 697K | US$22.5M | 0.54% |
| Alector, Inc. | 10M | US$20.1M | 0.48% |
| Forte Biosciences, Inc. | 920K | US$19.6M | 0.47% |
| Monopar Therapeutics Inc. | 203K | US$18.8M | 0.45% |
| Ocular Therapeutix, Inc. | 1.65M | US$16.2M | 0.39% |
| Alx Oncology Holdings Inc. | 5.66M | US$11.7M | 0.28% |
| Entrada Therapeutics, Inc. | 1.06M | US$7.8M | 0.19% |
| Cullinan Therapeutics, Inc. | 407K | US$7.41M | 0.18% |
| Arvinas, Inc. | 707K | US$5.88M | 0.14% |
| Korro Bio, Inc. | 416K | US$5.49M | 0.13% |
| Research Alliance Corporation Iii | 500K | US$5.35M | 0.13% |
| Leonabio, Inc. | 464K | US$4.27M | 0.10% |
| Jatt Ii Acquisition Corp | 200K | US$2.27M | 0.05% |
| Context Therapeutics Inc. | 2.68M | US$1.49M | 0.04% |
| Eikon Therapeutics, Inc. | 37,902 | US$495K | 0.01% |
| Upstream Bio, Inc. | 0 | US$0 | 0.00% |
| Vistagen Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Fulcrum Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Liquidia Corporation | 0 | US$0 | 0.00% |
Source
View original at SEC
Related